Friday, January 19, 2018 -- HBV reactivation occurs frequently in patients with chronic HBV and HCV coinfection receiving DAA therapy but is rare among patients with resolved HBV infection. Use of antiviral prophylaxis might be warranted in patients who test positive for hepatitis B surface antigen (HBsAg), particularly those with quantifiable HBV DNA.
Monday, January 08, 2018 -- PURPOSE Both chronic hepatitis C (HCV) and B virus (HBV) infections are generally asymptomatic, and many remain undetected or are diagnosed at a late stage. Studies that evaluate best practice hepatitis testing strategies are needed to better detect this hidden population. METHODS In this prospective cohort study, we aimed to determine the diagnostic yield (test uptake and rate of positive test results) of a combined public health and primary care birth cohort testing strategy in detecting hidden cases of HCV and HBV infections. We invited all patients aged between 40 and 70 years (n = 6,743) registered with 11 family practices serving 2 higher prevalence areas, or hotspots (ie, estimated HCV prevalence of 1%; national estimated prevalence is 0.1–0.4%),
Monday, January 08, 2018 -- Heplisav-B is the first and only two-dose vaccine for prevention of hepatitis B in adults.
Tuesday, December 26, 2017 -- (MedPage Today) -- Less than 10% of candidates got vaccine
Tuesday, December 19, 2017 -- Patient dosing commenced on December 18, 20174,800 subjects across two Phase 3 studies: PROTECT and CONSTANT 15-month program - headline data expected Q2 2019 CAMBRIDGE, Mass., Dec. 19, 2017 -- VBI Vaccines Inc....
Tuesday, December 19, 2017 -- In patients infected with hepatitis B, clinicians generally focus on liver disease and other hepatic disorders; however, comorbidities beyond the organ also may affect thorough management of the disease.
Wednesday, December 06, 2017 -- Arrowhead Pharmaceuticals (NASDAQ: ARWR) suffered a major setback last year after it canceled the development of three experimental drug candidates for liver disease. On Wednesday, Pasadena, CA-based Arrowhead—which houses its research and development operations in Madison, WI—shared data from a study involving one of the canceled drug candidates that the company believes could bode well […]
Wednesday, November 29, 2017 -- The Food and Drug Administration (FDA) has approved Heplisav-B for the prevention of infection caused by all known subtypes of hepatitis B virus.
Wednesday, November 22, 2017 -- The American College of Physicians (ACP) and Centers for Disease Control and Prevention (CDC) have joined forces to address chronic hepatitis B infections. A paper authored by the pair published in the Annals of Internal Medicine maintains reducing hepatitis B … Read More » The post Initiative targets hepatitis B infections appeared first on Life Science Daily.
Thursday, December 28, 2017 -- (MedPage Today) -- In mid-December, tofacitinib was approved for use in active psoriatic arthritis
Friday, November 17, 2017 -- by Louis-Marie Yindom, Maimuna Mendy, Christopher Bodimeade, Caroline Chambion, Peter Aka, Hilton C. Whittle, Sarah L. Rowland-Jones, Robert Walton Background Hepatocellular carcinoma (HCC) causes over 800,000 deaths worldwide annually, mainly in low income countries, and incidence is rising rapidly in the developed world with the spread of hepatitis B (HBV) and C (HCV) viruses. Natural Killer (NK) cells protect against viral infections and tumours by killing abnormal cells recognised by Killer-cell Immunoglobulin-like Receptors (KIR). Thus genes and haplotypes encoding these receptors may be important in determining both outcome of initial hepatitis infection and subsequent chronic liver disease and tumour formation. HBV is highly prevalent in The Gambia and the commonest cause of liver disease. The Gambia Liver Cancer Study
Wednesday, November 15, 2017 -- Michael JohnsenHeplisav-B is the first new hepatitis B vaccine in the United States in more than 25 years and the only two-dose hepatitis B vaccine for adults. read more
Monday, November 13, 2017 -- Heplisav-B becomes first and only two-dose hep B vaccine approved in the US
Saturday, November 11, 2017 -- On Thursday, Dynavax Technologies Corporation announced that the U.S. Food and Drug Administration (FDA) approved HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. HEPLISAV-B is the first new hepatitis B vaccine in the United States in more than 25 years and the […] The post Hepatitis B vaccine: HEPLISAV-B is 1st approval in US in 25 years, 1st two-shot vaccine appeared first on Outbreak News Today.
Friday, November 10, 2017 -- Officials with the FDA have approved an adjuvanted hepatitis B vaccine, recombinant [Heplisav-B, Dynavax] for the prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older.
Thursday, November 09, 2017 -- (Reuters) - Dynavax Technologies Corp's hepatitis B vaccine won the U.S. Food and Drug Administration's approval on the third attempt and Chief Executive Eddie Gray told Reuters the company was open to, but not waiting for, a partner to market the drug.
Tuesday, November 07, 2017 -- Research at the Southwest National Primate Research Center (SNPRC) on the campus of Texas Biomedical Research Institute helped advance a new treatment now in human trials for chronic hepatitis B virus (HBV) infection. Testing at SNPRC provided proof this novel therapeutic approach and drug delivery mechanism would be safe and effective, as recently published in […] The post Novel Hepatitis B treatment promising appeared first on Outbreak News Today.
Wednesday, November 01, 2017 -- Increased risk of liver cancer linked to hepatitis B DNA, surface antigen in a dose-response manner
Monday, October 30, 2017 -- Reviewed by Alan Gaby, MD Author: Fiorino S, et al Reference: Vitamin E for the treatment of E-antigen-positive chronic hepatitis B in paediatric patients: results of a randomized phase 2 controlled study. Liver Int 2017;37:54-61. Design: Randomized, open-label trial. Participants: Forty-three children (aged 2-17 years) with hepatitis B e-antigen (HBeAg)-positive chronic hepatitis B. Study Medication and Dosage: […]
Tuesday, October 24, 2017 -- by Barbora Lubyova, Jan Hodek, Ales Zabransky, Hana Prouzova, Martin Hubalek, Ivan Hirsch, Jan Weber In mammals, protein arginine methyltransferase 5, PRMT5, is the main type II enzyme responsible for the majority of symmetric dimethylarginine formation in polypeptides. Recent study reported that PRMT5 restricts Hepatitis B virus (HBV) replication through epigenetic repression of HBV DNA transcription and interference with encapsidation of pregenomic RNA. Here we demonstrate that PRMT5 interacts with the HBV core (HBc) protein and dimethylates arginine residues within the arginine-rich domain (ARD) of the carboxyl-terminus. ARD consists of four arginine rich subdomains, ARDI, ARDII, ARDIII and ARDIV. Mutation analysis of ARDs revealed that arginine methylation of HBc required the wild-type status of both ARDI and ARDII. Mass